Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Baxter International has initiated preclinical programs to develop recombinant Factor IX proteins to treat hemophilia B.
Subscribe to our email newsletter
Baxter will develop both an unmodified recombinant Factor IX therapy for treatment of acute bleeding episodes and a chemically modified, long-acting version of recombinant Factor IX therapy for prophylaxis of bleeding in hemophilia B patients.
Hartmut Ehrlich, vice president of global R&D for Baxter’s BioScience business, said: “Our goal is to develop an unmodified version of recombinant Factor IX intended for acute treatment of bleeding episodes in hemophilia B patients as well as to innovate a longer-acting Factor IX therapy for prevention of bleeding episodes. A longer-acting Factor IX may translate into few required infusions, and can help people living with hemophilia B lead a more normal, healthy life.”